Document is current
Any future updates will be listed below
-
Authors
Jobin, Benoît
Magdamo, Colin
Delphus, Daniela
Runde, Andreas
Reineke, Sean
Soto, Alysa Alejandro
Ergun, Beyzanur
Mukhija, Sasha
Albers, Alefiya Dhilla
Albers, Mark W.
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research
Fonds de Recherche du Québec - Santé
Réseau de Bio-Imagerie du Quebec
Université du Québec à Trois-Rivières
Mitacs
National Institutes of Health (R41AG062130, R41AG062130, R41AG062130, R41AG062130, R41AG062130, R41AG062130, R41AG062130, R41AG062130, R41AG062130)
- License Information
-
More Information
Article History
Received: 31 July 2024
Accepted: 3 March 2025
First Online: 24 March 2025
Declarations
:
: S.R. and M.W.A. are co-founders and own shares in Aromha, Inc. C.M. and A.D.A. are consultants for Aromha, Inc. M.W.A. and A.D.A.’s participation in this research was reviewed by the MGB Office of Industrial Interactions. M.W.A is a consultant for Sudo Bioscience Limited, Transposon Therapeutics, and has received in kind donations from IFF and from Eli Lilly. He has received speaking fees from Biohaven and Incyte. B.J., D.D., A.R., A.A.S., B.E., and S.M. have no competing interests to declare.
